Attached files
| file | filename |
|---|---|
| 8-K - Eloxx Pharmaceuticals, Inc. | v208729_8k.htm |
Senesco
Technologies Announces IND Filing With FDA For SNS01-T
NEW
BRUNSWICK, N.J. (January 24, 2011) -- Senesco Technologies, Inc. ("Senesco" or
the "Company") (NYSE Amex: SNT) today announced that the Company has filed an
Investigational New Drug (“IND”) application with the U.S. Food and Drug
Administration (“FDA”) for Senesco’s lead drug candidate SNS01-T for treatment
of multiple myeloma.
"Our
first IND submission is a significant milestone for Senesco,” stated Leslie J. Browne,
Ph.D, President and Chief Executive Officer of Senesco Technologies
Inc. “SNS01-T could be a new way of reprogramming cancer cells to respond
to natural death signals. It is designed to regulate what we believe is an
important growth control switch that induces programmed cell death, also known
as apoptosis. Senesco plans to evaluate SNS01-T in patients with relapsed or
refractory disease who have failed at least two standard treatment
regimens. If this therapeutic approach is successful, we believe it
has the potential to change the progression of the disease and significantly
impact patients' lives."
Multiple
myeloma is a cancer of plasma cells, a type of white blood
cell normally responsible for the production of antibodies, in which
abnormal cells accumulate in the bone marrow leading to bone lesions and
interfering with the production of normal blood cells. Up to two-thirds of
patients with the disease currently survive less than five years. Senesco was
previously granted orphan drug status for SNS01-T, the Company’s lead drug
candidate for treatment of multiple myeloma.
About
Senesco Technologies, Inc.
Senesco
Technologies is leveraging proprietary technology that regulates programmed cell
death, or apoptosis. Accelerating apoptosis may have application in treating
cancer, while delaying apoptosis may have application in certain inflammatory
and ischemic diseases. The Company is preparing to initiate a human clinical
trial in multiple myeloma with its lead therapeutic candidate, SNS01-T. Senesco
has already partnered with leading-edge companies engaged in agricultural
biotechnology, and is entitled to earn research and development milestones and
royalties if its gene-regulating platform technology is incorporated into its
partners’ products.
Forward-Looking
Statements
Certain
statements included in this press release are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Actual
results could differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to: the ability
of the Company to consummate additional financings; the development of the
Company’s gene technology; the approval of the Company’s patent applications;
the successful implementation of the Company’s research and development programs
and collaborations; the success of the Company's license agreements; the
acceptance by the market of the Company’s products; the success and timing of
the Company’s preliminary studies and preclinical research; competition and the
timing of projects and trends in future operating performance; the Company’s
ability to comply with the continued listing standards of the NYSE/AMEX; and
other factors expressed from time to time in the Company’s periodic filings with
the Securities and Exchange Commission (the "SEC"). As a result, this press
release should be read in conjunction with the Company’s periodic filings with
the SEC. The forward-looking statements contained herein are made only as of the
date of this press release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events or
circumstances.
Contact:
Senesco
Technologies, Inc.
Leslie J.
Browne, Ph.D.
President
& CEO
732-296-8400
or
Investor
Relations Contact:
CEOcast,
Inc.
Dan
Schustack, 212-732-4300
dschustack@ceocast.com